(CercleFinance.com) – AstraZeneca announced on Monday that a treatment based on Imfinzi had been shown to be effective in patients suffering from an operable type of lung cancer.
The combination of Imfinzi and chemotherapy – before and after surgery – improved patient survival without recurrence, disease progression or death by 32% compared to chemotherapy alone, according to the laboratory. .
The trial involved individuals with early operable non-small cell lung cancer.
This ‘statistically and clinically significant’ improvement compared to standard chemotherapy could prove decisive given that many patients suffering from this pathology see the disease return, explains the group.
Imfinzi (durvalumab) is a fully human monoclonal antibody against the PD-L1 protein that helps tumors evade detection and elimination by the immune system.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
